Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O95470

UPID:
SGPL1_HUMAN

ALTERNATIVE NAMES:
Sphingosine-1-phosphate aldolase

ALTERNATIVE UPACC:
O95470; B2RBD4; Q7Z732; Q9ULG8; Q9UN89

BACKGROUND:
The enzyme Sphingosine-1-phosphate lyase 1, also known as Sphingosine-1-phosphate aldolase, is integral to sphingolipid metabolism, facilitating the breakdown of sphingosine-1-phosphate. This process is vital for apoptosis, lipid, and cholesterol homeostasis. The protein's functions extend to modulating pro-inflammatory responses, neutrophil trafficking, and neuronal health, including autophagy and axonal maintenance.

THERAPEUTIC SIGNIFICANCE:
Linked to Nephrotic syndrome 14, a condition characterized by severe proteinuria and renal failure, Sphingosine-1-phosphate lyase 1's genetic variants underscore its clinical importance. Exploring this protein's mechanisms offers a promising avenue for developing targeted treatments for nephrotic syndrome and potentially other lipid-related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.